People taking weight loss jabs could be at risk of pancreas issues

GLP-1 medicines, such as tirzepatide (Mounjaro) and semaglutide (Wegovy) work by making people feel fuller for longer

Certain weight loss injections could put people at risk of a variety of side effects, some of which may even affect their pancreas. GLP-1 medicines, such as tirzepatide (Mounjaro) and semaglutide (Wegovy), work by making people feel fuller for longer, thus reducing hunger and the likelihood of overeating.

These medications are typically administered via an injection once a week over a prolonged period. NHS England guidelines emphasise that tirzepatide should only be used for weight management when eligible adults are obese and have other weight-related health issues, like hypertension or cardiovascular disease.

Similarly, the same guidelines recommend taking semag